Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208173 | 0.85 | MEN1 (0.52) | NR1H2ALOX5APFEN1MEN1ALDH1A1 | |
| SCHEMBL16612142 | 0.85 | MEN1 (0.52) | NR1H2ALOX5APFEN1MEN1ALDH1A1 | |
| SCHEMBL71546 | 0.84 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2ALOX5AP | |
| SCHEMBL20111214 | 0.84 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2ALOX5AP | |
| SCHEMBL1715488 | 0.83 | GPR119 (0.52) | USP2SMN1; SMN2HPGDRECQLEPHX1 | |
| SCHEMBL344307 | 0.82 | NR1H2 (0.58) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| SCHEMBL23585483 | 0.81 | NR1H2 (0.54) | NR1H2NAMPTUSP2SMN1; SMN2ALOX5AP | |
| SCHEMBL24500520 | 0.81 | NR1H2 (0.54) | NR1H2NAMPTUSP2SMN1; SMN2ALOX5AP | |
| Ammonia Solution, Strong SCHEMBL21723640 | 0.81 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL2527213 | 0.81 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883552-B1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250059191-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| US-12221443-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3067355-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067355-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| WO-2015053297-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2015-04-16 | — | — | WO | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2015046207-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | NR1H2 4374/4885NAMPT 832/4885USP2 1652/4885 |
| US-20250059191-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | NR1H2 3023/4885NAMPT 3303/4885USP2 3839/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | NR1H2 1408/4885NAMPT 963/4885USP2 2510/4885 |
| US-12221443-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | CCNA1, RCC1, DDT | NR1H2 3023/4885NAMPT 3303/4885USP2 3839/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | NR1H2 1402/4885NAMPT 783/4885USP2 2674/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | NR1H2 4374/4885NAMPT 832/4885USP2 1652/4885 |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | TYR, CUTA, BRAF | NR1H2 718/4885NAMPT 262/4885USP2 2535/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | NR1H2 4374/4885NAMPT 832/4885USP2 1652/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | NR1H2 311/4885NAMPT 3380/4885USP2 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.